AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11355097 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% fluoride varnish application and professional tooth-cleaning, motivation and instruction in oral hygiene (T)
Number of subjects: 419
Study 11355097 — intervention group
Group type: COMPARATOR
Intervention: Oral hygiene instruction and supervised toothbrushing once a year (C)
Number of subjects: 419
Study 9141006 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (given intramuscularly)
Number of subjects: 45
Study 9141006 — intervention group
Group type: COMPARATOR
Intervention: Control (conventional immunosuppression only)
Number of subjects: 45
Study 7967344 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultralow sodium dialysate (USD)
Number of subjects: 10
Study 7967344 — intervention group
Group type: COMPARATOR
Intervention: Normal sodium dialysate (NSD)
Number of subjects: 10
Study 3303815 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin and primary resuture
Number of subjects: 35
Study 3303815 — intervention group
Group type: COMPARATOR
Intervention: Not resutured but spontaneously healed
Number of subjects: 35
Study 31538418 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma Knife Radiosurgery (GKS)
Number of subjects: 264
Study 29455501 — intervention group
Group type: EXPERIMENTAL
Intervention: Core strength training group
Number of subjects: 80
Study 29455501 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation training group
Number of subjects: 80
Study 25467826 — intervention group
Group type: COMPARATOR
Intervention: 10-day standard sequential therapy
Number of subjects: 200
Study 25467826 — intervention group
Group type: EXPERIMENTAL
Intervention: levofloxacin-containing sequential therapy
Number of subjects: 200
Study 23420705 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-rotational angiography
Number of subjects: 80
Study 23420705 — intervention group
Group type: COMPARATOR
Intervention: Standard angiography
Number of subjects: 80
Study 22024610 — intervention group
Group type: COMPARATOR
Intervention: Hydrated (HY)
Number of subjects: 14
Study 22024610 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydrated (DHY)
Number of subjects: 14
Study 18647131 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive smoking cessation intervention including preoperative computerized counseling, tailored self-help material, brief advice from clinical staff, NRT, telephone counseling, and post-discharge support from a Quitline.
Number of subjects: 118
Study 18647131 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group.
Number of subjects: 118
Study 16938120 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient self-management (PSM) of anticoagulation therapy
Number of subjects: 617
Study 16938120 — intervention group
Group type: COMPARATOR
Intervention: Routine clinic-based care
Number of subjects: 617
Study 11823669 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured speed‐dependent treadmill training (STT)
Number of subjects: 60
Study 11823669 — intervention group
Group type: COMPARATOR
Intervention: Limited progressive treadmill training (LTT)
Number of subjects: 60
Study 11823669 — intervention group
Group type: COMPARATOR
Intervention: Conventional gait training (CGT)
Number of subjects: 60
Study 9950107 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg once daily for 3 days)
Number of subjects: 100
Study 9950107 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (625 mg every 8 hours for 10 days)
Number of subjects: 100
Study 7567310 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten (9 mg/kg daily for 10 days)
Number of subjects: 296
Study 7567310 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (40 mg/kg/day given every 8 hours for 10 days)
Number of subjects: 296
Study 7567310 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten
Number of subjects: 296
Study 7567310 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate
Number of subjects: 296
Study 2142611 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini Wright peak flow meter
Number of subjects: 212
Study 2142611 — intervention group
Group type: COMPARATOR
Intervention: Turbine spirometer
Number of subjects: 212
Study 6996138 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized senna tablets (Senokot; Reckitt & Colman)
Number of subjects: 189
Study 6996138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study 29173985 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week resistance training program focused on lower limbs
Number of subjects: 46
Study 27125669 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate 1.4 mg/m2 as a 2- to 5-min intravenous infusion on days 1 and 8 of each 21-day cycle
Number of subjects: 51
Study 27125669 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate
Number of subjects: 51
Study 24336820 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily co-trimoxazole (CMX) 800 mg/160 mg
Number of subjects: 264
Study 24336820 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine intermittent preventive treatment (IPT-SP)
Number of subjects: 264
Study 24336820 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily co-trimoxazole (CMX)
Number of subjects: 264
Study 22119661 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory alpha activity training (8-12Hz)
Number of subjects: 50
Study 22119661 — intervention group
Group type: COMPARATOR
Intervention: Random beta training
Number of subjects: 50
Study 22119661 — intervention group
Group type: COMPARATOR
Intervention: No training at all
Number of subjects: 50
Study 20452749 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial treatment
Number of subjects: 74
Study 18035081 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 3122
Study 18035081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3122
Study 16129801 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 1000
Study 16129801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 12017952 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural analgesia with fentanyl citrate plus bupivacaine using a low flow elastomerics infuser
Number of subjects: 50
Study 12017952 — intervention group
Group type: COMPARATOR
Intervention: Intermittent epidural analgesia with bupivacaine plus intravenous Ketorolaco
Number of subjects: 50
Study 10419117 — intervention group
Group type: EXPERIMENTAL
Intervention: High palmitic acid intake (16:0) with high 18:2n-6
Number of subjects: 0
Study 10419117 — intervention group
Group type: EXPERIMENTAL
Intervention: High palmitic acid intake (16:0) with low 18:2n-6
Number of subjects: 0
Study 10419117 — intervention group
Group type: EXPERIMENTAL
Intervention: Low palmitic acid intake (16:0) with high 18:2n-6
Number of subjects: 0
Study 10419117 — intervention group
Group type: EXPERIMENTAL
Intervention: Low palmitic acid intake (16:0) with low 18:2n-6
Number of subjects: 0
Study 10419117 — intervention group
Group type: EXPERIMENTAL
Intervention: High palmitic acid intake (16:0)
Number of subjects: 0
Study 10419117 — intervention group
Group type: EXPERIMENTAL
Intervention: Low palmitic acid intake (16:0)
Number of subjects: 0
Study 7492381 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF 5 micrograms/kg per day (n = 11)
Number of subjects: 20
Study 7492381 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 9)
Number of subjects: 20
Study 2255573 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (formula with predominantly 18:2 omega-6)
Number of subjects: 32
Study 2255573 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (balanced mix of 18:2 omega-6 and 18:3 omega-3)
Number of subjects: 32
Study 2255573 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (formula with essential fatty acids and supplemented with marine oil for 22:6 omega-3)
Number of subjects: 32
Study 2255573 — intervention group
Group type: COMPARATOR
Intervention: Human milk-fed group
Number of subjects: 32
Study 2255573 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 32
Study 2255573 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C
Number of subjects: 32
Study 6993548 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (CB-154)
Number of subjects: 32
Study 6993548 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose of CB-154 (5 mg po) one hour before arginine test
Number of subjects: 32
Study 6993548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 31740867 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-point fixation
Number of subjects: 60
Study 31740867 — intervention group
Group type: COMPARATOR
Intervention: Three-point fixation
Number of subjects: 60
Study 28049477 — intervention group
Group type: EXPERIMENTAL
Intervention: Bͻkͻͻ net fan systems (one fan per member)
Number of subjects: 83
Study 28049477 — intervention group
Group type: COMPARATOR
Intervention: Water filters
Number of subjects: 83
Study 28049477 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 83
Study 27872117 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care (neoadjuvant long course radiotherapy ± chemotherapy and APER)
Number of subjects: 0
Study 27872117 — intervention group
Group type: COMPARATOR
Intervention: APER surgery alone
Number of subjects: 0
Study 24560173 — intervention group
Group type: EXPERIMENTAL
Intervention: DFDBA plus lincomycin therapy
Number of subjects: 20
Study 24560173 — intervention group
Group type: COMPARATOR
Intervention: DFDBA alone (Control)
Number of subjects: 20
Study 22133470 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker up-titration to 12.5% of target dose
Number of subjects: 302
Study 22133470 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker up-titration to 25% of target dose
Number of subjects: 302
Study 22133470 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker up-titration to 50% of target dose
Number of subjects: 302
Study 22133470 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker up-titration to 100% of target dose
Number of subjects: 302
Study 22133470 — intervention group
Group type: COMPARATOR
Intervention: Groups 3/4 (50% and 100% target dose)
Number of subjects: 302
Study 22133470 — intervention group
Group type: COMPARATOR
Intervention: Groups 1/2 (12.5% and 25% target dose)
Number of subjects: 302
Study 19295389 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 61
Study 19295389 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anesthesia
Number of subjects: 61
Study 17959943 — intervention group
Group type: EXPERIMENTAL
Intervention: Greek tsatsiki with 4.2 g raw garlic (verum)
Number of subjects: 18
Study 17959943 — intervention group
Group type: COMPARATOR
Intervention: Greek tsatsiki without garlic (placebo)
Number of subjects: 18
Study 17959943 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily ingestion of 4.2 g of raw garlic over 1 week
Number of subjects: 18
Study 16296439 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐Step (one‐bottle bonding agent)
Number of subjects: 40
Study 16296439 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluma Desensitizer (glutaraldehyde‐based agent)
Number of subjects: 40
Study 16296439 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (control group)
Number of subjects: 40
Study 11983432 — intervention group
Group type: EXPERIMENTAL
Intervention: Global phase shift (PS)
Number of subjects: 0
Study 11983432 — intervention group
Group type: EXPERIMENTAL
Intervention: Local event onset shift (EOS)
Number of subjects: 0
Study 11983432 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbation magnitude up to +/‐15% of the sequence period (500 milliseconds)
Number of subjects: 0
Study 11983432 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger perturbations
Number of subjects: 0
Study 11983432 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized design and two additional task contexts
Number of subjects: 0
Study 10217550 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 mg/day transdermal nicotine patch (Nicoderm CQ)
Number of subjects: 56
Study 1322118 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping skills training
Number of subjects: 79
Study 1322118 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactional group psychotherapy
Number of subjects: 79
Study 6381610 — intervention group
Group type: EXPERIMENTAL
Intervention: HuIFN‐alpha 2 nasal drops (9 X 10(6) international units, three times a day for five days)
Number of subjects: 2
Study 6381610 — intervention group
Group type: EXPERIMENTAL
Intervention: HuIFN‐alpha 2 nasal spray (9 X 10(6) international units, three times a day for five days)
Number of subjects: 2
Study 6381610 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 2
Study 30848783 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (DE) 110
Number of subjects: 18113
Study 30848783 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (DE) 150
Number of subjects: 18113
Study 30848783 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 18113
Study 30848783 — intervention group
Group type: COMPARATOR
Intervention: Hospitalization (any reason)
Number of subjects: 18113
Study 30848783 — intervention group
Group type: COMPARATOR
Intervention: Cardiovascular hospitalization
Number of subjects: 18113
Study 29801943 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief interventions (BIs) without a specific topic in police custody settings
Number of subjects: 2000
Study 29801943 — intervention group
Group type: EXPERIMENTAL
Intervention: Four strategies for engaging in BIs
Number of subjects: 2000
Study 29801943 — intervention group
Group type: EXPERIMENTAL
Intervention: Determinants of success of the intervention
Number of subjects: 2000
Study 29801943 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement in BIs
Number of subjects: 2000
Study 27220276 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based brief motivational intervention
Number of subjects: 1449
Study 27220276 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 1449
Study 25920294 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Practice Guideline (CPG) compliance group
Number of subjects: 600
Study 25920294 — intervention group
Group type: COMPARATOR
Intervention: Clinical Practice Guideline (CPG) non-compliance group
Number of subjects: 600
Study 25920294 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CPG-compliant and non-compliant)
Number of subjects: 600
Study 23622801 — intervention group
Group type: COMPARATOR
Intervention: 14-day quadruple therapy (OMAB group) comprising omeprazole 20mg, metronidazole 500 mg, amoxicillin 1g, and bismuth subcitrate 240 mg
Number of subjects: 330
Study 23622801 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day triple regimen (OCP group) comprising omeprazole 20mg plus clarithromycin 500 mg and penbactam 750 mg
Number of subjects: 330
Study 23622801 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day triple regimen (OCA group) comprising omeprazole 20mg plus clarithromycin 500 mg and amoxicillin 1g
Number of subjects: 330
Study 21227000 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-sized Gateway(™) balloon and Wingspan(™) stent
Number of subjects: 72
Study 21227000 — intervention group
Group type: COMPARATOR
Intervention: Undersized Gateway(™) balloon and Wingspan(™) stent
Number of subjects: 72
Study 18665788 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE)
Number of subjects: 441
Study 18665788 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen (E) plus progestin (P)
Number of subjects: 441
Study 18665788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 441
Study 16803495 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical hysterectomy with or without adjuvant radiotherapy
Number of subjects: 94
Study 16803495 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant radiotherapy
Number of subjects: 94
Study 12869883 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg once daily for 28 days
Number of subjects: 208
Study 12869883 — intervention group
Group type: COMPARATOR
Intervention: Nizatidine 150 mg twice daily for 28 days
Number of subjects: 208
Study 10968855 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidewire sphincterotome (GS) without guidewire
Number of subjects: 100
Study 10968855 — intervention group
Group type: COMPARATOR
Intervention: Standard catheter
Number of subjects: 100
Study 10968855 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 9271971 — intervention group
Group type: EXPERIMENTAL
Intervention: One-to-one nurse support
Number of subjects: 413
Study 9271971 — intervention group
Group type: COMPARATOR
Intervention: Usual intrapartum nursing care
Number of subjects: 413
Study 8285627 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone at 2 g/day for 3 days
Number of subjects: 29
Study 8285627 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloramphenicol at 50 mg/kg of body weight per day for 14 days
Number of subjects: 29
Study 8285627 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 29
Study 8285627 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone and Chloramphenicol
Number of subjects: 29
Study 3556591 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant testosterone
Number of subjects: 155
Study 3556591 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment (Control)
Number of subjects: 155
Study 29745059 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of TNFi treatment
Number of subjects: 817
Study 29745059 — intervention group
Group type: COMPARATOR
Intervention: Continuation of TNFi treatment
Number of subjects: 817
Study 27791207 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Reflection Therapy (VRRT)
Number of subjects: 25
Study 27791207 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation program
Number of subjects: 25
Study 24919526 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 814
Study 22805297 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS fragmentation (fQRS) identified in inferior leads
Number of subjects: 1040
Study 22805297 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS fragmentation (fQRS) in patients with LBBB
Number of subjects: 1040
Study 20467596 — intervention group
Group type: EXPERIMENTAL
Intervention: Connective tissue grafts
Number of subjects: 10
Study 20467596 — intervention group
Group type: COMPARATOR
Intervention: No augmentation (Control)
Number of subjects: 10
Study 18946891 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard follow-up program in the heart failure clinic (HFC)
Number of subjects: 1250
Study 18946891 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP monitoring in the heart failure clinic (HFC)
Number of subjects: 1250
Study 18946891 — intervention group
Group type: COMPARATOR
Intervention: Treatment in general practice
Number of subjects: 1250
Study 16393726 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 88 microg bid
Number of subjects: 397
Study 16393726 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 220 microg bid
Number of subjects: 397
Study 16393726 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 440 microg bid
Number of subjects: 397
Study 16393726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 397
Study 16393726 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (all doses)
Number of subjects: 397
Study 12791224 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin
Number of subjects: 0
Study 12791224 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 10687572 — intervention group
Group type: EXPERIMENTAL
Intervention: Partogram with action line at 2 hours
Number of subjects: 615
Study 10687572 — intervention group
Group type: COMPARATOR
Intervention: Partogram with action line at 3 hours
Number of subjects: 615
Study 10687572 — intervention group
Group type: COMPARATOR
Intervention: Partogram with action line at 4 hours
Number of subjects: 615
Study 8728487 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg) administered at 1300 h
Number of subjects: 0
Study 8728487 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg) administered at 1800 h
Number of subjects: 0
Study 8728487 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg)
Number of subjects: 0
Study 1794818 — intervention group
Group type: EXPERIMENTAL
Intervention: Sezolamide 1.8% twice daily
Number of subjects: 36
Study 1794818 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5% twice daily
Number of subjects: 36
Study 6837251 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 2 mg perorally the night before operation and diazepam 0.2 mg per kg body weight perorally at 7.00 a.m. on the day of operation
Number of subjects: 62
Study 6837251 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 2 mg perorally the night before operation and morphine/scopolamine i.m. 1 h prior to operation
Number of subjects: 62
Study 6837251 — intervention group
Group type: COMPARATOR
Intervention: No flunitrazepam given on the night before operation, morphine/scopolamine i.m. 1 h preoperatively
Number of subjects: 62
Study 29992486 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise plus diet program (12-week, weekly aerobic exercise, 1200 kcal/day diet)
Number of subjects: 32
Study 29992486 — intervention group
Group type: COMPARATOR
Intervention: Usual activities (control group)
Number of subjects: 32
Study 29992486 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise plus diet program
Number of subjects: 32
Study 29851107 — intervention group
Group type: EXPERIMENTAL
Intervention: FMT-S (single faecal infusion via colonoscopy followed by a 14-day vancomycin course)
Number of subjects: 56
Study 29851107 — intervention group
Group type: COMPARATOR
Intervention: FMT-M (multiple faecal infusions plus a 14-day vancomycin course)
Number of subjects: 56
Study 29231361 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of ginger-isolated moxibustion and escitalopram (10 mg/day)
Number of subjects: 80
Study 29231361 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram (10 mg/day)
Number of subjects: 80